Patents Assigned to Mind Medicine, Inc. - Justia P
Post# of 64
(Total Views: 63)
Posted On: 08/06/2024 5:03:29 PM
Patents Assigned to Mind Medicine, Inc. - Justia Patents Search
https://patents.justia.com/assignee/mind-medicine-inc
Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
Patent number: 12036220
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Grant
Filed: April 3, 2023
Date of Patent: July 16, 2024
Assignee: Mind Medicine, Inc.
Inventors: Peter Mack, Timm Trenktrog, Dustin Melton, Bethany Amber Doty, Jon Schroeder, Lisa Marie Garrett
4-ALKENYL AND 4-ALKYNYL PHENETHYLAMINE DERIVATIVES AND RELATED COMPOUNDS WITH MODIFIED DOM-LIKE ACTION
Publication number: 20240174594
Abstract: A composition of a compound represented by FIGS. 1A-1E for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIGS. 1A-1E to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E and changing neurotransmission in the individual.
Type: Application
Filed: October 24, 2023
Publication date: May 30, 2024
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES
Publication number: 20240115710
Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.
Type: Application
Filed: December 18, 2023
Publication date: April 11, 2024
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
Synthesis routes to access MDMA prodrugs by using controlled and non-controlled intermediates
Patent number: 11896670
Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.
Type: Grant
Filed: August 23, 2022
Date of Patent: February 13, 2024
Assignee: Mind Medicine, Inc.
Inventors: Daniel Trachsel, Matthias Emanuel Liechti, Felix Lustenberger
METHODS OF MANUFACTURE OF R-MDMA
Publication number: 20240010628
Abstract: A method of manufacturing R-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with S-propylene oxide to form chirally pure alcohol 1, activating the alcohol as mesylate 2, converting to chirally pure azide 3, reducing the azide to amine 4, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 5 to yield R-MDMA free base 6, and treating with an acid to form a salt 7 in >99% e.e. A method of manufacturing S-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with R-propylene oxide to form chirally pure alcohol 8, activating the alcohol as mesylate 9, converting to chirally pure azide 10, reducing the azide to amine 11, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 12 to yield S-MDMA free base 13, and treating with an acid to form a salt 14 in >99% e.e.
Type: Application
Filed: June 29, 2023
Publication date: January 11, 2024
Applicant: Mind Medicine, Inc.
Inventors: Stephen E. SCHNEIDER, Derek LONDESBROUGH
LYSERGIC ACID DERIVATIVES WITH MODIFIED LSD-LIKE ACTION
Publication number: 20230414583
Abstract: A composition of a compound represented generically by FIG. 1A for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1A to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating an individual, by administering a pharmaceutically effective amount of a compound of FIG. 1A to the individual and treating the individual.
Type: Application
Filed: June 19, 2023
Publication date: December 28, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel Liechti, Felix Lustenberger
MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY
Publication number: 20230355575
Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.
Type: Application
Filed: May 16, 2023
Publication date: November 9, 2023
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
METHOD OF TITRATING DOSE OF PSYCHEDELICS
Publication number: 20230346645
Abstract: A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.
Type: Application
Filed: May 1, 2022
Publication date: November 2, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert Barrow, Daniel R. Karlin
MDMA ENANTIOMERS
Publication number: 20230310368
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: June 8, 2023
Publication date: October 5, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. Karlin, Gennady N. Smagin
18-MC SALT FORMS
Publication number: 20230303572
Abstract: A composition including a salt of 18-MC, wherein the salt is chosen from gentisate, hydrobromide, besylate, napadisylate, hydrochloride, sulfate, oxalate, maleate, mesylate, and tosylate. A composition including a polymorph of 18-MC.
Type: Application
Filed: March 1, 2023
Publication date: September 28, 2023
Applicant: Mind Medicine, Inc.
Inventors: Jeanne BONELLE, Daniel Emil LEVY, Ann NEWMAN, Stephen E. SCHNEIDER
MOVEMENT DISORDERS
Publication number: 20230301985
Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
Type: Application
Filed: May 16, 2023
Publication date: September 28, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN, Gennady SMAGIN
DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTION
Publication number: 20230285327
Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual.
Type: Application
Filed: May 12, 2023
Publication date: September 14, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230285386
Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.
Type: Application
Filed: May 18, 2023
Publication date: September 14, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY
FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY
Publication number: 20230285359
Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.
Type: Application
Filed: May 31, 2023
Publication date: September 14, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES
MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY
Publication number: 20230233688
Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, by administering proMDMA, a proMDMA-like compound, or proR(-)MDMA to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA, an MDMA-like substance or R(-)MDMA thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics present that would not be suitable for MDMA treatment and administering proMDMA, a proMDMA-like substance, or proR(-)MDMA to the individual. A method of reducing abuse of MDMA, by administering proMDMA, a proMDMA-like substance, or proR(-)MDMA, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.
Type: Application
Filed: March 28, 2023
Publication date: July 27, 2023
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
MDMA ENANTIOMERS
Publication number: 20230226019
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: March 20, 2023
Publication date: July 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
MDMA ENANTIOMERS
Publication number: 20230226020
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: March 20, 2023
Publication date: July 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
MESCALINE DERIVATIVES WITH MODIFIED ACTION
Publication number: 20230227398
Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1 - C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Zallylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Type: Application
Filed: March 27, 2023
Publication date: July 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230218532
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Application
Filed: April 3, 2023
Publication date: July 13, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
18-MC FOR TREATMENT OF SUBSTANCE USE DISORDERS
Publication number: 20230201217
Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures.
Type: Application
Filed: February 24, 2023
Publication date: June 29, 2023
Applicant: Mind Medicine, Inc.
Inventors: Scott FREEMAN, Stots B. REELE, Jeanne BONELLE
DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTION
Publication number: 20230150906
Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual.
Type: Application
Filed: November 16, 2022
Publication date: May 18, 2023
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230122949
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Application
Filed: December 7, 2022
Publication date: April 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230107398
Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.
Type: Application
Filed: December 7, 2022
Publication date: April 6, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY
MESCALINE DERIVATIVES WITH MODIFIED ACTION
Publication number: 20230091369
Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Type: Application
Filed: November 28, 2022
Publication date: March 23, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230075847
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Application
Filed: August 17, 2022
Publication date: March 9, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
18-MC for treatment of substance use disorders
Patent number: 11596638
Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures.
Type: Grant
Filed: October 1, 2020
Date of Patent: March 7, 2023
Assignee: Mind Medicine, Inc
Inventors: Scott Freeman, Stots B. Reele, Jeanne Bonelle
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230064429
Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.
Type: Application
Filed: August 17, 2022
Publication date: March 2, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL
SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES
Publication number: 20230066171
Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.
Type: Application
Filed: August 23, 2022
Publication date: March 2, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
SYSTEM AND METHOD FOR AUTOMATIC ANALYSIS OF TEXTS IN PSYCHOTHERAPY, COUNSELING, AND OTHER MENTAL HEALTH MANAGEMENT ACTIVITIES
Publication number: 20230053429
Abstract: A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.
Type: Application
Filed: August 17, 2022
Publication date: February 23, 2023
Applicant: Mind Medicine, Inc.
Inventors: Adam KOLAR, Martin MAJERNIK, Miguel Amavel dos Santos PINHEIRO, Daniel R. KARLIN, Robert BARROW
SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION
Publication number: 20230000431
Abstract: A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.
Type: Application
Filed: June 13, 2022
Publication date: January 5, 2023
Applicant: Mind Medicine, Inc.
Inventors: Martin MAJERNIK, Daniel R. KARLIN, Robert BARROW, Peter DUBEC
18-MC FOR TREATING OBESITY
Publication number: 20220409628
Abstract: A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity. A method of treating binge eating, by administering an effective amount of the composition to an individual and treating binge eating. A method of treating behavioral addictions, by administering an effective amount of the composition to an individual and treating the behavioral addiction.
Type: Application
Filed: June 8, 2022
Publication date: December 29, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
System and method for patient monitoring of gastrointestinal function using automated stool classifications
Patent number: 11532396
Abstract: A method of data collection of stool data via a mobile device operable to enable monitoring of gastrointestinal function. A related method of long-term monitoring of patient gastrointestinal function, using one or more signal processing tools (e.g. machine learning algorithms) for automatically interpreting patient stool data, including real-time patient-assessments, in order to detect an adverse clinical event from patient stool data. A system for facilitating real-time monitoring the gastrointestinal function, the system comprising: a camera on a mobile device, a user interface that facilitates self-monitoring of stool characteristics, so as to create health-monitoring data; mobile device storage, server storage, and remote storage (with at least one communication link between them) for storing some or all of the health-monitoring data; and a processor for interpreting such health-monitoring data for clinical or other health-monitoring application.
Type: Grant
Filed: June 12, 2020
Date of Patent: December 20, 2022
Assignee: Mind Medicine, Inc.
Inventors: Daniel R Karlin, Peter Dubec, Martin Majernik, Vladimir Boza, Lucia Kvapilova, Dana Rajtarova
CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION
Publication number: 20220395499
Abstract: A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug. A method of stopping psychosis due to psychedelic administration, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug, and stopping psychosis caused by the psychedelic drug.
Type: Application
Filed: June 6, 2022
Publication date: December 15, 2022
Applicant: Mind Medicine, Inc.
Inventors: Daniel R. KARLIN, Robert BARROW
FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY
Publication number: 20220370413
Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.
Type: Application
Filed: August 8, 2022
Publication date: November 24, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES, JR.
PSYCHEDELICS FOR TREATMENT OF PAIN
Publication number: 20220362237
Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual. A method of treating a pain syndrome, by administering an effective amount of a psychedelic to an individual, and providing a central effect, an effect on depression, and an inflammatory effect.
Type: Application
Filed: July 29, 2022
Publication date: November 17, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R KARLIN
MDMA ENANTIOMERS
Publication number: 20220354822
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: May 1, 2022
Publication date: November 10, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
LIPOSOME DELIVERY OF PSYCHEDELICS
Publication number: 20220354862
Abstract: A composition of a psychedelic in a liposome formulation, wherein the composition provides preferential distribution of the psychedelic at the CNS and blood, and reduced distribution at peripheral organs. A method of treating a patient, by administering a composition of a psychedelic in a liposome formulation to the patient, and preferentially distributing the psychedelic at the CNS with a reduced exposure in target peripheral organs (e.g., heart).
Type: Application
Filed: April 29, 2022
Publication date: November 10, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Gennady N. SMAGIN
MOVEMENT DISORDERS
Publication number: 20220354831
Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
Type: Application
Filed: May 1, 2022
Publication date: November 10, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
LSD SALT CRYSTAL FORMS
Publication number: 20220348575
Abstract: Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms. A pharmaceutical formulation of polymorphic forms of LSD in crystalline salt forms including pharmaceutically acceptable excipients. Polymorphic forms of LSD free-base. Polymorphic forms of a salt form of LSD.
Type: Application
Filed: April 26, 2022
Publication date: November 3, 2022
Applicant: Mind Medicine, Inc.
Inventors: Daniel Emil LEVY, Stephen E. SCHNEIDER
PSYCHEDELICS FOR TREATMENT OF PAIN
Publication number: 20220347195
Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.
Type: Application
Filed: April 29, 2022
Publication date: November 3, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R KARLIN
FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY
Publication number: 20220280482
Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual, and treating the disease or condition.
Type: Application
Filed: March 4, 2022
Publication date: September 8, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER
MESCALINE DERIVATIVES WITH MODIFIED ACTION
Publication number: 20220267252
Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Type: Application
Filed: February 20, 2022
Publication date: August 25, 2022
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY
Publication number: 20220151986
Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.
Type: Application
Filed: November 4, 2021
Publication date: May 19, 2022
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
USE OF 3-METHYLMETHCATHINONE
Publication number: 20200360311
Abstract: The present invention relates to methods of drug-assisted psychotherapy with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects undergoing psychotherapeutic intervention. In particular, methods and kits for drug-assisted psychotherapy with 3-MMC for a variety of disorders and/or conditions, including PTSD, GAD and relationship distress are provided.
Type: Application
Filed: August 2, 2018
Publication date: November 19, 2020
Applicant: Mind Medicine, Inc.
Inventors: Ezekiel GOLAN, Mark HADEN, Rene VAN WETTUM
https://patents.justia.com/assignee/mind-medicine-inc
Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
Patent number: 12036220
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Grant
Filed: April 3, 2023
Date of Patent: July 16, 2024
Assignee: Mind Medicine, Inc.
Inventors: Peter Mack, Timm Trenktrog, Dustin Melton, Bethany Amber Doty, Jon Schroeder, Lisa Marie Garrett
4-ALKENYL AND 4-ALKYNYL PHENETHYLAMINE DERIVATIVES AND RELATED COMPOUNDS WITH MODIFIED DOM-LIKE ACTION
Publication number: 20240174594
Abstract: A composition of a compound represented by FIGS. 1A-1E for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIGS. 1A-1E to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E and changing neurotransmission in the individual.
Type: Application
Filed: October 24, 2023
Publication date: May 30, 2024
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES
Publication number: 20240115710
Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.
Type: Application
Filed: December 18, 2023
Publication date: April 11, 2024
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
Synthesis routes to access MDMA prodrugs by using controlled and non-controlled intermediates
Patent number: 11896670
Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.
Type: Grant
Filed: August 23, 2022
Date of Patent: February 13, 2024
Assignee: Mind Medicine, Inc.
Inventors: Daniel Trachsel, Matthias Emanuel Liechti, Felix Lustenberger
METHODS OF MANUFACTURE OF R-MDMA
Publication number: 20240010628
Abstract: A method of manufacturing R-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with S-propylene oxide to form chirally pure alcohol 1, activating the alcohol as mesylate 2, converting to chirally pure azide 3, reducing the azide to amine 4, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 5 to yield R-MDMA free base 6, and treating with an acid to form a salt 7 in >99% e.e. A method of manufacturing S-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with R-propylene oxide to form chirally pure alcohol 8, activating the alcohol as mesylate 9, converting to chirally pure azide 10, reducing the azide to amine 11, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 12 to yield S-MDMA free base 13, and treating with an acid to form a salt 14 in >99% e.e.
Type: Application
Filed: June 29, 2023
Publication date: January 11, 2024
Applicant: Mind Medicine, Inc.
Inventors: Stephen E. SCHNEIDER, Derek LONDESBROUGH
LYSERGIC ACID DERIVATIVES WITH MODIFIED LSD-LIKE ACTION
Publication number: 20230414583
Abstract: A composition of a compound represented generically by FIG. 1A for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1A to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating an individual, by administering a pharmaceutically effective amount of a compound of FIG. 1A to the individual and treating the individual.
Type: Application
Filed: June 19, 2023
Publication date: December 28, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel Liechti, Felix Lustenberger
MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY
Publication number: 20230355575
Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.
Type: Application
Filed: May 16, 2023
Publication date: November 9, 2023
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
METHOD OF TITRATING DOSE OF PSYCHEDELICS
Publication number: 20230346645
Abstract: A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.
Type: Application
Filed: May 1, 2022
Publication date: November 2, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert Barrow, Daniel R. Karlin
MDMA ENANTIOMERS
Publication number: 20230310368
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: June 8, 2023
Publication date: October 5, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. Karlin, Gennady N. Smagin
18-MC SALT FORMS
Publication number: 20230303572
Abstract: A composition including a salt of 18-MC, wherein the salt is chosen from gentisate, hydrobromide, besylate, napadisylate, hydrochloride, sulfate, oxalate, maleate, mesylate, and tosylate. A composition including a polymorph of 18-MC.
Type: Application
Filed: March 1, 2023
Publication date: September 28, 2023
Applicant: Mind Medicine, Inc.
Inventors: Jeanne BONELLE, Daniel Emil LEVY, Ann NEWMAN, Stephen E. SCHNEIDER
MOVEMENT DISORDERS
Publication number: 20230301985
Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
Type: Application
Filed: May 16, 2023
Publication date: September 28, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN, Gennady SMAGIN
DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTION
Publication number: 20230285327
Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual.
Type: Application
Filed: May 12, 2023
Publication date: September 14, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230285386
Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.
Type: Application
Filed: May 18, 2023
Publication date: September 14, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY
FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY
Publication number: 20230285359
Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.
Type: Application
Filed: May 31, 2023
Publication date: September 14, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES
MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY
Publication number: 20230233688
Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, by administering proMDMA, a proMDMA-like compound, or proR(-)MDMA to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA, an MDMA-like substance or R(-)MDMA thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics present that would not be suitable for MDMA treatment and administering proMDMA, a proMDMA-like substance, or proR(-)MDMA to the individual. A method of reducing abuse of MDMA, by administering proMDMA, a proMDMA-like substance, or proR(-)MDMA, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.
Type: Application
Filed: March 28, 2023
Publication date: July 27, 2023
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
MDMA ENANTIOMERS
Publication number: 20230226019
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: March 20, 2023
Publication date: July 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
MDMA ENANTIOMERS
Publication number: 20230226020
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: March 20, 2023
Publication date: July 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
MESCALINE DERIVATIVES WITH MODIFIED ACTION
Publication number: 20230227398
Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1 - C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Zallylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Type: Application
Filed: March 27, 2023
Publication date: July 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230218532
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Application
Filed: April 3, 2023
Publication date: July 13, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
18-MC FOR TREATMENT OF SUBSTANCE USE DISORDERS
Publication number: 20230201217
Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures.
Type: Application
Filed: February 24, 2023
Publication date: June 29, 2023
Applicant: Mind Medicine, Inc.
Inventors: Scott FREEMAN, Stots B. REELE, Jeanne BONELLE
DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTION
Publication number: 20230150906
Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual.
Type: Application
Filed: November 16, 2022
Publication date: May 18, 2023
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230122949
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Application
Filed: December 7, 2022
Publication date: April 20, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230107398
Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.
Type: Application
Filed: December 7, 2022
Publication date: April 6, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY
MESCALINE DERIVATIVES WITH MODIFIED ACTION
Publication number: 20230091369
Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Type: Application
Filed: November 28, 2022
Publication date: March 23, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230075847
Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
Type: Application
Filed: August 17, 2022
Publication date: March 9, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
18-MC for treatment of substance use disorders
Patent number: 11596638
Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures.
Type: Grant
Filed: October 1, 2020
Date of Patent: March 7, 2023
Assignee: Mind Medicine, Inc
Inventors: Scott Freeman, Stots B. Reele, Jeanne Bonelle
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Publication number: 20230064429
Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.
Type: Application
Filed: August 17, 2022
Publication date: March 2, 2023
Applicant: Mind Medicine, Inc.
Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL
SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES
Publication number: 20230066171
Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.
Type: Application
Filed: August 23, 2022
Publication date: March 2, 2023
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
SYSTEM AND METHOD FOR AUTOMATIC ANALYSIS OF TEXTS IN PSYCHOTHERAPY, COUNSELING, AND OTHER MENTAL HEALTH MANAGEMENT ACTIVITIES
Publication number: 20230053429
Abstract: A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.
Type: Application
Filed: August 17, 2022
Publication date: February 23, 2023
Applicant: Mind Medicine, Inc.
Inventors: Adam KOLAR, Martin MAJERNIK, Miguel Amavel dos Santos PINHEIRO, Daniel R. KARLIN, Robert BARROW
SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION
Publication number: 20230000431
Abstract: A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.
Type: Application
Filed: June 13, 2022
Publication date: January 5, 2023
Applicant: Mind Medicine, Inc.
Inventors: Martin MAJERNIK, Daniel R. KARLIN, Robert BARROW, Peter DUBEC
18-MC FOR TREATING OBESITY
Publication number: 20220409628
Abstract: A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity. A method of treating binge eating, by administering an effective amount of the composition to an individual and treating binge eating. A method of treating behavioral addictions, by administering an effective amount of the composition to an individual and treating the behavioral addiction.
Type: Application
Filed: June 8, 2022
Publication date: December 29, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
System and method for patient monitoring of gastrointestinal function using automated stool classifications
Patent number: 11532396
Abstract: A method of data collection of stool data via a mobile device operable to enable monitoring of gastrointestinal function. A related method of long-term monitoring of patient gastrointestinal function, using one or more signal processing tools (e.g. machine learning algorithms) for automatically interpreting patient stool data, including real-time patient-assessments, in order to detect an adverse clinical event from patient stool data. A system for facilitating real-time monitoring the gastrointestinal function, the system comprising: a camera on a mobile device, a user interface that facilitates self-monitoring of stool characteristics, so as to create health-monitoring data; mobile device storage, server storage, and remote storage (with at least one communication link between them) for storing some or all of the health-monitoring data; and a processor for interpreting such health-monitoring data for clinical or other health-monitoring application.
Type: Grant
Filed: June 12, 2020
Date of Patent: December 20, 2022
Assignee: Mind Medicine, Inc.
Inventors: Daniel R Karlin, Peter Dubec, Martin Majernik, Vladimir Boza, Lucia Kvapilova, Dana Rajtarova
CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION
Publication number: 20220395499
Abstract: A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug. A method of stopping psychosis due to psychedelic administration, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug, and stopping psychosis caused by the psychedelic drug.
Type: Application
Filed: June 6, 2022
Publication date: December 15, 2022
Applicant: Mind Medicine, Inc.
Inventors: Daniel R. KARLIN, Robert BARROW
FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY
Publication number: 20220370413
Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.
Type: Application
Filed: August 8, 2022
Publication date: November 24, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES, JR.
PSYCHEDELICS FOR TREATMENT OF PAIN
Publication number: 20220362237
Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual. A method of treating a pain syndrome, by administering an effective amount of a psychedelic to an individual, and providing a central effect, an effect on depression, and an inflammatory effect.
Type: Application
Filed: July 29, 2022
Publication date: November 17, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R KARLIN
MDMA ENANTIOMERS
Publication number: 20220354822
Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
Type: Application
Filed: May 1, 2022
Publication date: November 10, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
LIPOSOME DELIVERY OF PSYCHEDELICS
Publication number: 20220354862
Abstract: A composition of a psychedelic in a liposome formulation, wherein the composition provides preferential distribution of the psychedelic at the CNS and blood, and reduced distribution at peripheral organs. A method of treating a patient, by administering a composition of a psychedelic in a liposome formulation to the patient, and preferentially distributing the psychedelic at the CNS with a reduced exposure in target peripheral organs (e.g., heart).
Type: Application
Filed: April 29, 2022
Publication date: November 10, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Gennady N. SMAGIN
MOVEMENT DISORDERS
Publication number: 20220354831
Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
Type: Application
Filed: May 1, 2022
Publication date: November 10, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R. KARLIN
LSD SALT CRYSTAL FORMS
Publication number: 20220348575
Abstract: Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms. A pharmaceutical formulation of polymorphic forms of LSD in crystalline salt forms including pharmaceutically acceptable excipients. Polymorphic forms of LSD free-base. Polymorphic forms of a salt form of LSD.
Type: Application
Filed: April 26, 2022
Publication date: November 3, 2022
Applicant: Mind Medicine, Inc.
Inventors: Daniel Emil LEVY, Stephen E. SCHNEIDER
PSYCHEDELICS FOR TREATMENT OF PAIN
Publication number: 20220347195
Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.
Type: Application
Filed: April 29, 2022
Publication date: November 3, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Daniel R KARLIN
FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY
Publication number: 20220280482
Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual, and treating the disease or condition.
Type: Application
Filed: March 4, 2022
Publication date: September 8, 2022
Applicant: Mind Medicine, Inc.
Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER
MESCALINE DERIVATIVES WITH MODIFIED ACTION
Publication number: 20220267252
Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Type: Application
Filed: February 20, 2022
Publication date: August 25, 2022
Applicant: Mind Medicine, Inc.
Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY
Publication number: 20220151986
Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.
Type: Application
Filed: November 4, 2021
Publication date: May 19, 2022
Applicant: Mind Medicine, Inc.
Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
USE OF 3-METHYLMETHCATHINONE
Publication number: 20200360311
Abstract: The present invention relates to methods of drug-assisted psychotherapy with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects undergoing psychotherapeutic intervention. In particular, methods and kits for drug-assisted psychotherapy with 3-MMC for a variety of disorders and/or conditions, including PTSD, GAD and relationship distress are provided.
Type: Application
Filed: August 2, 2018
Publication date: November 19, 2020
Applicant: Mind Medicine, Inc.
Inventors: Ezekiel GOLAN, Mark HADEN, Rene VAN WETTUM
(0)
(0)Mind Medicine Inc (MNMD) Stock Research Links
Scroll down for more posts ▼